The results of the genomic data can guide treatment decisions post-surgery in prostate cancer.
A genomic classifier may be effective in predicting the risk of biochemical failure and distant metastasis in post-surgery radiation in patients with prostate cancer who have undergone radical prostatectomy, according to recent findings.
These findings suggest utility for a genomic classifier in deciding a patient’s course of treatment after radical prostatectomy, particularly in terms of identifying which patients will benefit from additional radiation.
“We are moving away from treating everyone the same,” researcher Robert Den, MD, assistant professor of radiation oncology and cancer biology at Thomas Jefferson University in Philadelphia, said in a press release. “Genomic tools are letting us gauge which cancers are more aggressive and should be treated earlier with radiation, and which ones are unlikely to benefit from additional therapy.”
Read the complete article: http://bit.ly/1q7xV9j